Owned and operated by a cf veteran 
Independent analytical report
Retatrutide 10 mg — Task 103184
Review the report details, original PDF and Janoshik verification record.
Report summary
- Compound
- Retatrutide
- Strength
- 10 mg
- Reported purity
- 99.520%
- Tested quantity
- 12.42 mg
- Report date
- January 29, 2026
- Janoshik task ID
- #103184
This January 2026 analysis returned 12.42 mg of Retatrutide at 99.520 percent purity, with the laboratory work conducted on 29 January.
Like the other GLP-1 submissions, it was run as a blind panel covering Semaglutide, Tirzepatide and Retatrutide rather than a single-target assay. The record sits between the October 2025 and July 2026 analyses of the 10 mg presentation and is retained so the full sequence of testing stays visible rather than being replaced.
This certificate describes the submitted sample identified in the report. It does not establish clinical safety, efficacy, suitability for human or veterinary use, or the specifications of future inventory.